{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:30:45Z","timestamp":1792002645396,"version":"4.4.0"},"reference-count":157,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.4155\/fmc.12.80","type":"journal-article","created":{"date-parts":[[2012,8,2]],"date-time":"2012-08-02T12:04:18Z","timestamp":1343909058000},"page":"1439-1460","source":"Crossref","is-referenced-by-count":161,"title":["Histone Deacetylase Inhibitors In The Treatment Of Cancer: Overview And Perspectives"],"prefix":"10.1080","volume":"4","author":[{"given":"Giuseppe","family":"Giannini","sequence":"first","affiliation":[{"name":"Medicinal Chemistry, Oncology, R&D, Corporate Sigma-Tau S.p.A, Via Pontina, km 30,400I-00040Pomezia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Cabri","sequence":"additional","affiliation":[{"name":"Preclinical Development, R&D, Corporate Sigma-Tau S.p.A, Via Pontina, km 30,400I-00040Pomezia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Fattorusso","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica delle Sostanze Naturali, Universit\u00e0 di Napoli, Via D. Montesano, 49I-80131Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Rodriquez","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Farmaceutiche e Biomediche, Universit\u00e0 di Salerno, Via Ponte don Melillo, I-84084Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2012,8,2]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.51.5.786"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.42.24674"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81063-6"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5260.408"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.250422697"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210613"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2227"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1272"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2011.35"},{"key":"e_1_3_2_3_10_1","first-page":"1","article-title":"Issa J-PJ. Epigenetics in cancer: what\u2019s the future","volume":"25","author":"Boumber Y","year":"2011","unstructured":"Boumber Y , Issa J-PJ. Epigenetics in cancer: what\u2019s the future. Oncology25, 1\u201313 (2011).","journal-title":"Oncology"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200461346"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.20024"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986706776360905"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.2174\/138955711795843347"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.9.1.135"},{"key":"e_1_3_2_3_16_1","unstructured":"Marks PA RichonVM MillerTA KellyWK. Histone deacetylase inhibitors: new targeted anticancer drugs. In: Cancer: Principles and Practice of Oncology (7th Edition). DeVita VT Jr Hellman S Rosenberg SA (Eds). Lippincott Williams & Wilkins Philadelphia PA USA 439\u2013445 (2005)."},{"key":"e_1_3_2_3_17_1","first-page":"371832","article-title":"Physical and functional HAT\/HDAC interplay regulates protein acetylation balance.","author":"Peserico A","year":"2011","unstructured":"Peserico A , SimoneC. Physical and functional HAT\/HDAC interplay regulates protein acetylation balance.J. Biomed. Biotechnol.371832 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2346"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj20021321"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2004.02.006"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2010.510514"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.8.2873-2884.2005"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2005.09.010"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.06.026"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.08.016"},{"key":"e_1_3_2_3_26_1","first-page":"462","article-title":"Histone deacetylase inhibitors in the treatment of lymphoma.","volume":"10","author":"Lemoine M","year":"2010","unstructured":"Lemoine M , YounesA. Histone deacetylase inhibitors in the treatment of lymphoma.Discov. Med.10, 462\u2013470 (2010).","journal-title":"Discov. Med."},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-07-0324"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.19.8467-8476.2004"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2004.02.002"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24144"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(00)01551-6"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.embor941"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.969202"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.18.8166-8178.2005"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81531-7"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076469"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(01)00429-4"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M301922200"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M104935200"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706487104"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0437870100"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M803514200"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488410791498770"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2008.03109.x"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.10.047"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja9615841"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.10.082"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2010.02.030"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2008.12.008"},{"key":"e_1_3_2_3_50_1","first-page":"3923","article-title":"Ligand based pharmacophore modelling of anticancer histone deacetylase inhibitors.","volume":"9","author":"Noureen N","year":"2010","unstructured":"Noureen N , KalsoomS, RashidH. Ligand based pharmacophore modelling of anticancer histone deacetylase inhibitors.Afr. J. Biotech.9, 3923\u20133931 (2010).","journal-title":"Afr. J. Biotech."},{"key":"e_1_3_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.12.5705"},{"key":"e_1_3_2_3_52_1","first-page":"5165","article-title":"Suberoylanilide hydroxamic acid, an in vivo inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.","volume":"60","author":"Butler LM","year":"2000","unstructured":"Butler LM , AgusDB, ScherHIet al. Suberoylanilide hydroxamic acid, an in vivo inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60, 5165\u20135170 (2000).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.73.3.862"},{"key":"e_1_3_2_3_54_1","first-page":"3137","article-title":"A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of compound library.","volume":"60","author":"Su GH","year":"2000","unstructured":"Su GH , SohnTA, RyuB, KernSE. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of compound library.Cancer Res.60, 3137\u20133142 (2000).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja0341440"},{"key":"e_1_3_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.06.090"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.09.014"},{"key":"e_1_3_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm8002894"},{"key":"e_1_3_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.02.029"},{"key":"e_1_3_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm101092u"},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm200577a"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.29.1"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4020(01)89789-1"},{"key":"e_1_3_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm030235w"},{"key":"e_1_3_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja9613724"},{"key":"e_1_3_2_3_66_1","first-page":"4916","article-title":"FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.","volume":"62","author":"Furumai R","year":"2002","unstructured":"Furumai R , MatsuyamaA, KobashiNet al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62, 4916\u20134921 (2002).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_67_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.47.301"},{"key":"e_1_3_2_3_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/hlca.19740570306"},{"key":"e_1_3_2_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4039(00)85846-3"},{"key":"e_1_3_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.36.478"},{"key":"e_1_3_2_3_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.198903331"},{"key":"e_1_3_2_3_72_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.43.1524"},{"key":"e_1_3_2_3_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)41547-5"},{"key":"e_1_3_2_3_74_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.23.13143"},{"key":"e_1_3_2_3_75_1","doi-asserted-by":"publisher","DOI":"10.1021\/jo016088w"},{"key":"e_1_3_2_3_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(00)00604-1"},{"key":"e_1_3_2_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(00)00605-3"},{"key":"e_1_3_2_3_78_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.56.72"},{"key":"e_1_3_2_3_79_1","doi-asserted-by":"publisher","DOI":"10.1021\/ol050991r"},{"key":"e_1_3_2_3_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200501995"},{"key":"e_1_3_2_3_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200700095"},{"key":"e_1_3_2_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2008.08.003"},{"key":"e_1_3_2_3_83_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm980565u"},{"key":"e_1_3_2_3_84_1","first-page":"3008","article-title":"Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cell.","volume":"53","author":"El-Beltagi HM","year":"1993","unstructured":"El-Beltagi HM , MartensACM, LelievedP, HarounEA, HagenbeekA. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cell.Cancer Res.53, 3008\u20133014 (1993).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.08.083"},{"key":"e_1_3_2_3_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(02)00754-0"},{"key":"e_1_3_2_3_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.09.007"},{"key":"e_1_3_2_3_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200900309"},{"key":"e_1_3_2_3_89_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm101373a"},{"key":"e_1_3_2_3_90_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408732102"},{"key":"e_1_3_2_3_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2133"},{"key":"e_1_3_2_3_92_1","first-page":"245","article-title":"The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.","volume":"5","author":"Van Lint C","year":"1996","unstructured":"Van Lint C , EmilianiS, VerdinE. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.Gene Expr.5, 245\u2013253 (1996).","journal-title":"Gene Expr."},{"key":"e_1_3_2_3_93_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.2.2.349"},{"key":"e_1_3_2_3_94_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.180316197"},{"key":"e_1_3_2_3_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401182"},{"key":"e_1_3_2_3_96_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M313120200"},{"key":"e_1_3_2_3_97_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.18.8097-8107.2005"},{"key":"e_1_3_2_3_98_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01926-05"},{"key":"e_1_3_2_3_99_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.23.12.4162-4173.2003"},{"key":"e_1_3_2_3_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207654"},{"key":"e_1_3_2_3_101_1","first-page":"45","article-title":"Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells.","volume":"24","author":"Lee EM","year":"2009","unstructured":"Lee EM , ShinS, ChaHJet al. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int. J. Mol. Med. 24, 45\u201350 (2009).","journal-title":"Int. J. Mol. Med."},{"key":"e_1_3_2_3_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207893"},{"key":"e_1_3_2_3_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401686"},{"key":"e_1_3_2_3_104_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0505585102"},{"key":"e_1_3_2_3_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd772"},{"key":"e_1_3_2_3_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1160"},{"key":"e_1_3_2_3_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.306"},{"key":"e_1_3_2_3_108_1","first-page":"887","article-title":"LGP1, a histone deacetylase inhibitor analogue of FR235222, sensitizes promyelocytic leukaemia U937 cells to TRAIL-mediated apoptosis.","volume":"30","author":"D\u2018Acunto CW","year":"2010","unstructured":"D\u2018Acunto CW , CarratuA, RodriquezM, TaddeiM, ParenteL, PetrellaA. LGP1, a histone deacetylase inhibitor analogue of FR235222, sensitizes promyelocytic leukaemia U937 cells to TRAIL-mediated apoptosis.Anticancer Res.30, 887\u2013894 (2010).","journal-title":"Anticancer Res."},{"key":"e_1_3_2_3_109_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.5.6.2700"},{"key":"e_1_3_2_3_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63098-2"},{"key":"e_1_3_2_3_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2010.02.016"},{"key":"e_1_3_2_3_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.01.023"},{"key":"e_1_3_2_3_113_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607518103"},{"key":"e_1_3_2_3_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210620"},{"key":"e_1_3_2_3_115_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.45.120403.095825"},{"key":"e_1_3_2_3_116_1","first-page":"175","article-title":"HDAC inhibitors and cancer therapy, epigenetics and disease.","volume":"67","author":"Atadja PW","year":"2011","unstructured":"Atadja PW . HDAC inhibitors and cancer therapy, epigenetics and disease.Prog. Drug Res.67, 175\u2013195 (2011).","journal-title":"Prog. Drug Res."},{"key":"e_1_3_2_3_117_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e03-01-0860"},{"key":"e_1_3_2_3_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/35055010"},{"key":"e_1_3_2_3_119_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.4.2.1441"},{"key":"e_1_3_2_3_120_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.4.5.1690"},{"key":"e_1_3_2_3_121_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191208598"},{"key":"e_1_3_2_3_122_1","first-page":"3637","article-title":"The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1\/WAF1 1.","volume":"63","author":"Rosato RR","year":"2003","unstructured":"Rosato RR , AlmenaraJA, GrantS. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1\/WAF1 1.Cancer Res.63, 3637\u20133645 (2003).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.11.012"},{"key":"e_1_3_2_3_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)01085-1"},{"key":"e_1_3_2_3_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205108"},{"key":"e_1_3_2_3_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.03.037"},{"key":"e_1_3_2_3_127_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.5.21.3409"},{"key":"e_1_3_2_3_128_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.26.6.2019-2028.2006"},{"key":"e_1_3_2_3_129_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4598"},{"key":"e_1_3_2_3_130_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152012800228706"},{"key":"e_1_3_2_3_131_1","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2009.42.10.655"},{"key":"e_1_3_2_3_132_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3033525"},{"key":"e_1_3_2_3_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0311-262"},{"key":"e_1_3_2_3_134_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.22185"},{"key":"e_1_3_2_3_135_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2485"},{"key":"e_1_3_2_3_136_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13148-010-0012-4"},{"key":"e_1_3_2_3_137_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543770903393789"},{"key":"e_1_3_2_3_138_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.57.897"},{"key":"e_1_3_2_3_139_1","doi-asserted-by":"publisher","DOI":"10.2165\/11315680-000000000-00000"},{"key":"e_1_3_2_3_140_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1759"},{"key":"e_1_3_2_3_141_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.121"},{"key":"e_1_3_2_3_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.12.001"},{"key":"e_1_3_2_3_143_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0913912107"},{"key":"e_1_3_2_3_144_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019711"},{"key":"e_1_3_2_3_145_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707166"},{"key":"e_1_3_2_3_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67074-2"},{"key":"e_1_3_2_3_147_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2011.97"},{"key":"e_1_3_2_3_148_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05772"},{"key":"e_1_3_2_3_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2009.06.002"},{"key":"e_1_3_2_3_150_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1989"},{"key":"e_1_3_2_3_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2005.08.007"},{"key":"e_1_3_2_3_152_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1479"},{"key":"e_1_3_2_3_153_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707165"},{"key":"e_1_3_2_3_154_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986707780362880"},{"key":"e_1_3_2_3_155_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2011.100"},{"key":"e_1_3_2_4_2_1","unstructured":"RCSB Protein Data Bank. www.rcsb.org\/pdb\/explore.do?structureId=1t69"},{"key":"e_1_3_2_4_3_1","unstructured":"Clinicaltrials.gov. www.clinicaltrials.gov"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc.12.80","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:50:27Z","timestamp":1716479427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc.12.80"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":157,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.4155\/fmc.12.80"],"URL":"https:\/\/doi.org\/10.4155\/fmc.12.80","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}